Goodbye, Dolly: Rejecting Cloned Food
By Dr. Allan Kornberg,
Business Week
| 02. 21. 2007
Ten years after scientists produced the first clone of a mammal, a sheep named Dolly, the U.S. Food and Drug Administration has issued a draft assessment that moves our nation closer to the widespread sale of meat and dairy products from animal clones.
During the next two months, Americans have the opportunity to comment on the FDA's draft and influence whether or not food from animal clones ends up in our fast food and on our supermarket shelves. Debate is under way on the possible long-term risk to human health, consumer choice, and religious and ethical concerns. The one group that stands to lose the most if the FDA's assessment is accepted is the farm animals that will suffer and die to produce food and dairy products that most Americans don't want to eat. Since animals cannot speak, those of us who care about animal welfare must speak out for them.
"Unconscionable"
Over the past decade, news of Dolly's birth and subsequent announcements that scientists succeeded in producing clones of cows, pigs, goats, and other animals—even cats and dogs—have been...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...